Struggling to understand why stroke is progressing so slowly. I don't think manufacturing is an issue. Clinuvel is losing advantage as Argenica Therapeutics grinds through their Phase 2 stroke trial. It's not too late for Clinuvel to press ahead, they have the added advantage of an already approved molecule. I think any concerns over threats to the safety profile due to patients passing away in the stroke trial is overweight, there was a patient that passed away and they still proceeded with the trial. And considering the size of the TAM, there is plenty of room for competition.
Argenica are planning to market their drug for use with first responders so presumably it will be in vials/depot style or an EpiPen type delivery system. Keen to see if Prenumbra Instant will be similar, that will enable Clinuvel to go toe to toe with Argenica. All is not lost yet, but they need to start making some waves with stroke and soon.
Struggling to understand why stroke is progressing so slowly. I...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.37 |
Change
0.180(1.36%) |
Mkt cap ! $669.5M | |||
| Open | High | Low | Value | Volume |
| $13.19 | $13.59 | $13.13 | $1.181M | 88.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 606 | $13.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.51 | 282 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |